Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Guangzhou Baiyunshan Pharmaceu (600332 CH)
Watchlist
48
Analysis
Health Care
•
China
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. manufactures and sells Chinese patent medicine. The Company also wholesales, retails, imports, and exports Western and Chinese pharmaceutical products and various medical apparatus.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Guangzhou Baiyunshan Pharmaceu
•
28 Apr 2026 02:05
Primer: Guangzhou Baiyunshan Pharmaceu (600332 CH) - Apr 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. is a leading, vertically integrated pharmaceutical company in China with a diverse...
αSK Primers
126 Views
Share
bullish
•
Quantitative Analysis
•
11 Oct 2026 10:15
A-H Premium Weekly (Oct 9th): Innocare, Ganfenglithium, China East Air, Yofc
We analyzed A-H premium changes in the past week and highlight A-H premium changes for Innocare, Ganfenglithium, China East Air, Yofc.
Ke Yan, CFA, FRM
Follow
87 Views
Share
bullish
•
Quantitative Analysis
•
06 Sep 2026 10:15
A-H Premium Weekly (Sep 4th): China South Air, Remegen, China Telecom, Muyuan Foods, Conch Cement
We analyzed A-H premium changes in the past week and highlight A-H premium changes for China South Air, Remegen, China Telecom, Muyuan Foods, Conch...
Ke Yan, CFA, FRM
Follow
104 Views
Share
bullish
•
Quantitative Analysis
•
30 Aug 2026 10:15
A-H Premium Weekly (Aug 28th): Gwmotor, China Mobile, Remegen, Fuyao Glass, Minsheng Bank
We analyzed A-H premium changes in the past week and highlight A-H premium changes for Gwmotor, China Mobile, Remegen, Fuyao Glass, Minsheng Bank.
Ke Yan, CFA, FRM
Follow
106 Views
Share
bullish
•
Thematic (Sector/Industry)
•
13 Jun 2023 08:55
The Cyclicality of China Healthcare - Policy Environment, the Industry, and Investment Opportunities
Without industry beta, China healthcare companies still have opportunity to achieve countercyclical breakthrough.Investors need to be in line with...
Xinyao (Criss) Wang
Follow
533 Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x